Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Lunch and Poster Display session

34P - Premenopausal breast cancer and CYP27A1 expression: A cholesterol-associated biomarker

Date

16 May 2024

Session

Lunch and Poster Display session

Presenters

Jeppe Skovbjerg

Citation

Annals of Oncology (2024) 9 (suppl_4): 1-34. 10.1016/esmoop/esmoop103010

Authors

J. Skovbjerg1, D. Cronin-Fenton2, K. Lystlund Lauridsen3, T.P. Ahern4, S. Hamilton Dutoit3, S. Borgquist5

Author affiliations

  • 1 Aarhus University Hospital, Aarhus/DK
  • 2 Aarhus University and Aarhus University Hospital, Aarhus N/DK
  • 3 Aarhus University Hospital, Aarhus N/DK
  • 4 University of Vermont - Larner College of Medicine, Burlington/US
  • 5 Aarhus University and Aarhus University Hospital, Aarhus/DK

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 34P

Background

An important link between hypercholesterolemia and breast cancer (BC) prognosis may be the cholesterol metabolite 27-hydroxycholesterol (27HC) acting as an estrogen receptor (ER) ligand and catalysed by the CYP27A1 enzyme. This study aimed to investigate the prognostic value of CYP27A1 expression in a large population-based cohort of premenopausal women with BC.

Methods

We included 4,684 premenopausal women diagnosed with stage I-III BC between 2002-2011 and registered in the Danish Breast Cancer Group clinical database. We assessed CYP27A1 expression using immunohistochemistry on tissue microarrays. CYP27A1-expression was categorized in four intensity levels: 0(absent), 1(weak), 2(moderate), 3(strong), and dichotomized into low (0,1) and high(2,3). We followed patients from date of BC primary surgery to the first of BC recurrence, death, emigration, or 10 years of follow up. We evaluated the association of CYP27A1-expression with BC recurrence and mortality using Cox regression estimating hazard ratios (HR) and associated 95% confidence intervals (95%CI) adjusting for patient, tumor, and treatment characteristics.

Results

Tumor expression of CYP27A1 was successfully assessed in 4,241 patients with a median follow-up of 7.5 years, during which 787 disease-free survival (DFS) events occurred. Tumors with high CYP27A1-expression occurred more frequently among patients with younger age at diagnosis, higher histological grade, ER negativity, progesterone receptor negativity and HER2 normality. Overall, there was little evidence of an association between CYP27A1-expression and DFS in the entire cohort (HRadj 0.90 [95%CI 0.72-1.11]) or in the ER-positive subgroup (n=3,330) (HRadj 0.92 [95%CI 0.71-1.19]). High CYP27A1-expression was associated with improved DFS among patients with ER-negative tumors (n=911): (HRcru 0.69 [95%CI 0.53-0.89]). The adjusted analyses showed similar, although less precise estimates (n=492): (HRadj 0.82 [95%CI 0.55-1.21].

Conclusions

High tumor CYP27A1-expression may be associated with improved prognosis among premenopausal ER-negative BC patients. This association needs testing in larger cohorts, preferably containing both pre- and postmenopausal patients.

Legal entity responsible for the study

The authors.

Funding

Aarhus University, A.P. Møller Fonden, Kræftafdelingens Forskningsfond.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.